Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...